1-5 of 5
Kelly Jacques
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex

Free
Jessie Hao-Ru Hsu, Timothy Rasmusson, James Robinson, Fiona Pachl, Jon Read, Sameer Kawatkar, Daniel H O'Donovan, Sharan Bagal, Erin Code, Philip Rawlins, Argyrides Argyrou, Ronald Tomlinson, Ning Gao, Xiahui Zhu, Elisabetta Chiarparin, Kelly Jacques, Minhui Shen, Haley Woods, Emma Bednarski, David M. Wilson, Lisa Drew, M. Paola Castaldi, Stephen Fawell, Andrew Bloecher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): LB-A09.
https://doi.org/10.1158/1535-7163.TARG-19-LB-A09
Published: 01 December 2019
View article titled, Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex
Journal Articles

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Free
Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D'Cruz, Michael Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, Emma L. Jenkins
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2441–2451.
https://doi.org/10.1158/1535-7163.MCT-15-0230
Published: 03 November 2015
View article titled, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Open the PDF for Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract C274: FGF receptor mutations and fusions are therapeutic targets for inhibition by AZD4547.

Free
Christopher R. Denz, Nin Guan, Kelly Jacques, Elaine Kilgour, Emma Jenkins, Sylvie Guichard, Paul Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C274.
https://doi.org/10.1158/1535-7163.TARG-13-C274
Published: 01 November 2013
View article titled, Abstract C274: FGF receptor mutations and fusions are therapeutic targets for inhibition by AZD4547.
Journal Articles

Abstract C55: Discovery and optimization of inhibitors of the KIFC1 motor protein.

Free
Michelle L. Lamb, Jiaquan Wu, Keith Mikule, Wendy Wang, Nancy Su, Philip Petteruti, Farzin Gharahdaghi, Erin Code, Xiahui Zhu, Kelly Jacques, Zhongwu Lai, Tao Zhang, David Boulay, Gurmit Grewal, Nicholas Keen, Bin Yang, Claudio Chuaqui, Claudio Chuaqui, Huawei Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C55.
https://doi.org/10.1158/1535-7163.TARG-13-C55
Published: 01 November 2013
View article titled, Abstract C55: Discovery and optimization of inhibitors of the KIFC1 motor protein.
Journal Articles

Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Free
Nin Guan, Oona Delpuech, Danielle Greenawalt, Kelly Jacques, Farzin Gharahdaghi, Michael Zinda, Paul J. Smith, Sylvie M. Guichard
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C144.
https://doi.org/10.1158/1535-7163.TARG-13-C144
Published: 01 November 2013
View article titled, Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.